GlaxoSmithKline wins recommendation to sell Alli in Europe

LONDON GlaxoSmithKline won a recommendation from European regulators Thursday that it be allowed to sell its weight loss drug Alli over-the-counter in Europe.

The European Medicines Agency said it had recommended the switch from prescription-only to nonprescription for a 60-milligram dose of alli, the same dose approved for sale OTC in the United States. The European Commission now needs to rubber-stamp the recommendation.

The European Medicines Agency said it had recommended the switch from prescription-only to nonprescription for a 60-milligram dose of alli, the same dose approved for sale OTC in the United States. The European Commission now needs to rubber-stamp the recommendation.